HC Wainwright Reaffirms Buy Rating for Evaxion A/S (NASDAQ:EVAX)

Evaxion A/S (NASDAQ:EVAX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $16.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 297.02% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Wall Street Zen lowered shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Maxim Group started coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price target for the company. JonesTrading started coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price target for the company. Finally, Lake Street Capital reduced their price target on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evaxion A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Down 5.2%

Shares of NASDAQ EVAX opened at $4.03 on Friday. The firm has a market cap of $33.61 million, a PE ratio of -3.05 and a beta of 0.19. Evaxion A/S has a 12-month low of $1.42 and a 12-month high of $12.15. The company’s fifty day simple moving average is $3.74 and its 200 day simple moving average is $4.74. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41.

Hedge Funds Weigh In On Evaxion A/S

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Evaxion A/S in the fourth quarter valued at approximately $38,000. Wesbanco Bank Inc. bought a new position in shares of Evaxion A/S in the fourth quarter valued at approximately $48,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S in the fourth quarter valued at approximately $72,000. 11.04% of the stock is currently owned by institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.